Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/67751
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEdel, Michael John-
dc.contributor.authorMenchón Najas, Cristina-
dc.contributor.authorMenendez, Sergio-
dc.contributor.authorConsiglio, Antonella-
dc.contributor.authorRaya Chamorro, Ángel-
dc.contributor.authorIzpisúa Belmonte, Juan Carlos-
dc.date.accessioned2015-11-12T08:51:45Z-
dc.date.available2015-11-12T08:51:45Z-
dc.date.issued2010-03-15-
dc.identifier.issn1549-5477-
dc.identifier.urihttp://hdl.handle.net/2445/67751-
dc.description.abstractHuman pluripotent stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), have the unique abilities of differentiation into any cell type of the organism (pluripotency) and indefinite self-renewal. Here, we show that the Rem2 GTPase, a suppressor of the p53 pathway, is up-regulated in hESCs and, by loss- and gain-of-function studies, that it is a major player in the maintenance of hESC self-renewal and pluripotency. We show that Rem2 mediates the fibroblastic growth factor 2 (FGF2) signaling pathway to maintain proliferation of hESCs. We demonstrate that Rem2 effects are mediated by suppressing the transcriptional activity of p53 and cyclin D(1) to maintain survival of hESCs. Importantly, Rem2 does this by preventing protein degradation during DNA damage. Given that Rem2 maintains hESCs, we also show that it is as efficient as c-Myc by enhancing reprogramming of human somatic cells into iPSCs eightfold. Rem2 does this by accelerating the cell cycle and protecting from apoptosis via its effects on cyclin D(1) expression/localization and suppression of p53 transcription. We show that the effects of Rem2 on cyclin D(1) are independent of p53 function. These results define the cell cycle and apoptosis as a rate-limiting step during the reprogramming phenomena. Our studies highlight the possibility of reprogramming somatic cells by imposing hESC-specific cell cycle features for making safer iPSCs for cell therapy use.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1101/gad.1876710-
dc.relation.ispartofGenes and Development, 2010, vol. 24, num. 6, p. 561-573-
dc.relation.urihttp://dx.doi.org/10.1101/gad.1876710-
dc.rightscc-by-nc (c) Edel, Michael John et al., 2010-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)-
dc.subject.classificationCèl·lules mare embrionàries-
dc.subject.classificationTeràpia genètica-
dc.subject.classificationGenètica molecular-
dc.subject.classificationCicle cel·lular-
dc.subject.otherEmbryonic stem cells-
dc.subject.otherGene therapy-
dc.subject.otherMolecular genetics-
dc.subject.otherCell cycle-
dc.titleRem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec650723-
dc.date.updated2015-11-12T08:51:46Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid20231315-
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
650723.pdf2.1 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons